NEWS

Medical group endorses anti-malarial drug treatment for coronavirus patients

America’s major medical society specializing in the treatment of respiratory diseases has endorsed using hydroxychloroquine for seriously ill hospitalized coronavirus patients.

The American Thoracic Society issued guidelines Monday that suggest COVID-19 patients with pneumonia get doses of the anti-malaria drug.

“To prescribe hydroxychloroquine (or chloroquine) to hospitalized patients with COVID-19 pneumonia if all of the following apply: a) shared decision-making is possible, b) data can be collected for interim comparisons of patients who received hydroxychloroquine (or chloroquine) versus those who did not, c) the illness is sufficiently severe to warrant investigational therapy, and d) the drug is not in short supply,” the Thoracic Society said.

The use of hydroxychloroquine has been hotly debated.

President Trump has promoted its use on an experimental basis and Gov. Andrew Cuomo has agreed to provide it to thousands of seriously ill patients in New York hospitals in combination with Zithromax.

Critics have criticized the promotion of using the drug based on limited or anecdotal evidence.

The Thoracic Society said its guidelines are based on input from an international task force comprised of doctors from medical centers that are currently treating COVID-19 patients.

The medical group said evidence about the impact of hydroxychloroquine is “contradictory” but it is worth experimenting with during a public health crisis to treat very sick patients.

“We believe that in urgent situations like a pandemic, we can learn while treating by collecting real-world data,” said Dr. Kevin Wilson, chief of Guidelines and Documents at the American Thoracic Society.

“There are in vitro studies that suggest that hydroxychloroquine and chloroquine have activity against SARS-CoV-2019, the virus that causes COVID-19,” Wilson said.

But he also said several controlled trials from China and France “all have serious flaws and inconsistent findings. ….Thus, the bottom line is, whether hydroxychloroquine and chloroquine confer benefits to patients with COVID-19 are unanswered questions.”

 

This article was originally published on independenteagle.com

Recent news

Reduce plastic pollution to preserve all marine life

Oceans play a vital role in life on earth, a role that affects humans in… Read more

Plastic pollution: World's oceans may have more than double the amount of tiny plastic particles than scientists thought

Using finer nets, scientists catch double the number of microplastic particles There might be more… Read more

A circular economy of plastics will reduce plastic pollution and slow down climate change

Plastics have extremely useful properties: they help us keep our food fresh, make it possible… Read more

Long-term data show hurricanes are getting stronger

In almost every region of the world where hurricanes form, their maximum sustained winds are… Read more

Bacteria: The Ultimate Environmentalist

Because of their reputation for causing illness, bacteria are not often viewed in a positive… Read more

Why electric vehicles are going to take over the world

Interesting times in the electric vehicle market, as more and more carmakers try to position… Read more

Tesla eyeing Austin, Tulsa for next electric vehicle assembly plant, according to reports

Could Tesla build its new Cybertruck in Texas? Tesla is eyeing Tulsa and Austin as… Read more

What to Look for in an Eco-Friendly Building Contractor

The transition to sustainability is happening in every industry. Building and home contractors are also… Read more

Mussels that clump together in reefs may ingest triple the plastic

The impact of plastic on the many species that call the ocean home is a… Read more

Powerhouse: the startup making solar the most accessible energy in the world

It’s one of the only incubators focused on solar companies – but Powerhouse is part… Read more